Please login to the form below
Horizon
This page shows the latest Horizon news and features for those working in and with pharma, biotech and healthcare.
Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition
At the time of the request, concern was rising among investors regarding the FTC’s decision to block Amgen’s proposed $27.8bn takeover of Horizon Therapeutics. ... The Amgen/Horizon transaction has since been allowed to proceed after a proposed
Latest news
-
Bristol Myers Squibb reveals plans to double number of drugs in registrational trials
In addition to its growing registrational portfolio, the company said it has more than 25 indication expansion opportunities “on the horizon” and nine “high-potential” early assets expected to advance in
-
UK rejoins Horizon Europe research initiative under new bespoke agreement
The UK is set to rejoin the Horizon Europe research initiative through a bespoke new agreement with the EU. ... contracts. Horizon will provide UK companies and research institutions with opportunities to lead global work to develop new technologies and
-
Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement
to "entrench the monopoly positions" of Horizon’s thyroid eye disease drug Tepezza and gout treatment Krystexxa. ... Amgen said it has consistently stated that it has no reason, ability or intention to bundle Horizon’s two drugs with any of its
-
US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition
proposed $27.8bn takeover of Horizon Therapeutics has caused concern among investors. ... of Horizon’s thyroid eye disease drug Tepezza and gout treatment Krystexxa.
-
Horizon shares positive results for Uplizna in neuromyelitis optica spectrum disorder
Horizon Therapeutics has shared positive new MRI data from a late-stage study of Uplizna (inebilizumab-cdon) in patients with neuromyelitis optica spectrum disorder (NMOSD). ... A new analysis of MRI data from the phase 3 N-MOmentum trial, presented by
More from news
Approximately 24 fully matching, plus 163 partially matching documents found.
Latest Intelligence
-
The rise of biologics: is the sector ready for future demand?
Today, leading biologics manufacturers such as Pfizer, BMS, Janssen, Amgen, Sanofi, Takeda, including leading emerging names like MeiraGTx, Horizon, Alexion, BioMarin, have their tech ops and manufacturing sites (bulk drug,
-
Don’t go for the easy option – step up, break out, stand out
You can almost see the sun drop below the horizon, the stock photo of a carefree couple walking hand-in-hand along the beach.
-
Powering creativity to work in harmony with science and data
Companies need creativity at the heart of their output – with social media and new channels presenting new horizons and challenges.
-
The 17th World Congress on Controversies in Neurology
The ‘living-talking’ photographic display was organised by Horizon Therapeutics, the global biotech, to give the patients a platform and raise awareness among clinicians and KoLs. ... Horizon was founded with a handful of employees in 2008 by CEO Tim
-
Using the power of data to future-proof the clinical development industry
Budgets are being squeezed, economic disruption is on the horizon and the clinical development industry is bracing itself for a new set of global challenges. ... Data-led, patient-centric. Major disruption can drive innovation. With further challenges on
More from intelligence
Approximately 0 fully matching, plus 69 partially matching documents found.
Latest appointments
-
CureVac’s CEO appointed to EC High Level Group
Dr Ingmar Hoerr will advise on Horizon 2020 and future innovation programmes. ... Dr Hoerr joins a panel of 15 group members who will advise the EC on how to strengthen support for breakthrough, market-creating innovation in the Horizon 2020 project as
-
Decibel Therapeutics expands leadership team
He co-founded Bright Horizons Family Solutions, a worksite childcare and early education provider, and prior to this served as co-director of Save the Children's Sudan operations.
-
Eric Rhodes becomes CEO of ERS Genomics
Rhodes joins ERS Genomics from Horizon Discovery, where he served as senior vice president of research and development and chief technology officer. ... Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of
-
Jane Osbourn to chair BIA board
The new members of the board are Darrin Disley, chief executive of Horizon Discovery Group and David Hipkiss, chief business officer at Circassia Pharmaceuticals.
-
Adaptimmune appoints Lawrence Alleva to its board
He currently serves as a director for public companies Tesaro and Bright Horizons Family Solutions, and for the privately-held Mirna Therapeutics, and chairs those companies' audit committees.
More from appointments
Approximately 3 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
Putting prevention at the heart of the future of the NHS
Instead, the Government must look beyond the horizon – focusing on the preventative measures that can contribute towards improving the overall health of our nation, reduce the burden faced by the NHS
-
Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. ... The brief. In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new
-
Welcome to the era of the orphan drug
Thankfully, owing to the considerable research efforts of the global scientific community, vaccines have been rolled-out and the promise of normality is on the horizon.
-
We Need To Talk About We Don’t Talk About Bruno
The princess (literal or otherwise) stares at the horizon and sings about the life she wants.
-
Future focus: 3 tools for launching fast in the face of uncertainty
You could see the barriers that would impact your clinical trials, the siloes slowing down decision making, and even look far into the horizon to understand how your product launch would
More from PMHub
Approximately 0 fully matching, plus 44 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
